Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
adenocarcinoma in situ
cervical intraepithelial neoplasia
human papillomavirus
invasive cervical cancer
vaccine
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
31
03
2020
revised:
29
04
2020
accepted:
30
04
2020
pubmed:
7
5
2020
medline:
11
8
2020
entrez:
7
5
2020
Statut:
ppublish
Résumé
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type-specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type-specific RCs between CIN1 and CIN2-3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type-specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2-3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2-3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01-4.98), followed by HPV31 (2.51, 1.54-5.24), HPV18 (2.43, 1.59-4.32), HPV35 (1.56, 0.43-8.36), HPV33 (1.01, 0.49-3.31), HPV52 (0.99, 0.76-1.33), and HPV58 (0.97, 0.75-1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71-2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14-0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9-valent vaccine contributed to 89.7% (95% CI, 88.7-90.7) of CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9-valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.
Identifiants
pubmed: 32372453
doi: 10.1111/cas.14445
pmc: PMC7385338
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2546-2557Subventions
Organisme : Japan Agency of Medical Research and Development (AMED)
ID : 20fk0108098
Organisme : MEXT KAKENHI
ID : 17K11297
Organisme : Foundation for Advancement of International Science (FAIS)
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Cancer Sci. 2020 Jul;111(7):2546-2557
pubmed: 32372453
PLoS One. 2020 Jan 29;15(1):e0228042
pubmed: 31995585
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
J Gen Virol. 2020 Mar;101(3):265-270
pubmed: 31859615
Cancer Sci. 2009 Jul;100(7):1312-6
pubmed: 19432906
Obstet Gynecol. 2004 Feb;103(2):304-9
pubmed: 14754700
J Clin Virol. 2016 Mar;76 Suppl 1:S49-S55
pubmed: 26643050
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Jpn J Clin Oncol. 2014 Oct;44(10):1000-3
pubmed: 25098705
Papillomavirus Res. 2018 Dec;6:46-51
pubmed: 30401640
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
N Engl J Med. 2007 Oct 18;357(16):1579-88
pubmed: 17942871
Infect Agent Cancer. 2012 Dec 29;7(1):38
pubmed: 23273245
Int J Cancer. 2004 Aug 20;111(2):278-85
pubmed: 15197783
Cancer Res. 2019 Mar 15;79(6):1252-1259
pubmed: 30635276
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Int J Cancer. 2016 Jun 15;138(12):2795-803
pubmed: 26661889
Int J Cancer. 2019 May 1;144(9):2144-2152
pubmed: 30474210
J Obstet Gynaecol Res. 2019 Apr;45(4):766-786
pubmed: 30675969
Int J Cancer. 2011 Jun 15;128(12):2898-910
pubmed: 20734388
Jpn J Clin Oncol. 2014 Oct;44(10):910-7
pubmed: 25156680
Cancer Sci. 2019 Dec;110(12):3811-3820
pubmed: 31596999
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Cancer. 1996 Nov 1;78(9):1935-41
pubmed: 8909314
JAMA. 2007 Aug 15;298(7):743-53
pubmed: 17699008
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
BMC Med. 2019 Dec 11;17(1):228
pubmed: 31829241